Patents by Inventor D. Davidson Easson

D. Davidson Easson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Underivatized, aqueous soluble beta(1-3) glucan, composition and method of making same
    Publication number: 20040116380
    Abstract: The present invention relates to neutral, aqueous soluble &bgr;-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel &bgr;-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble &bgr;-glucan preparation has a high affinity for the &bgr; glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemo-poietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble &bgr;-glucan of this invention neither induces nor primes IL-1&bgr; and TNF&agr; production in vitro and in vivo.
    Type: Application
    Filed: November 21, 2003
    Publication date: June 17, 2004
    Inventors: Spiros Jamas, D. Davidson Easson, Gary R. Ostroff
  • Very high molecular weight beta-glucans
    Publication number: 20020143174
    Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble &bgr;-glucan composition comprising &bgr;-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).
    Type: Application
    Filed: March 7, 2002
    Publication date: October 3, 2002
    Applicant: Biopolymer Engineering, Inc.
    Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Gary R. Ostroff
  • Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same
    Publication number: 20020032170
    Abstract: The present invention relates to neutral, aqueous soluble &bgr;-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel &bgr;-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble &bgr;-glucan preparation has a high affinity for the &bgr;-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble &bgr;-glucan of this invention neither induces nor primes IL-1&bgr;, and TNF&agr; production in vitro and in vivo.
    Type: Application
    Filed: April 24, 2001
    Publication date: March 14, 2002
    Inventors: Spiros Jamas, D. Davidson Easson, Gary R. Ostroff